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Genome-wide analysisThe pathogenesis of microsatellite stable hereditary non-polyposis colorectal cancers (MSS HNPCC) is
unclear. To identify genomic regions that might be involved in MSS HNPCC pathogenesis, we selected 20
pairs of MSS HNPCC for a genome-wide study using copy number variation targeted (CNV-targeted)
CytoScan HD Array. A remarkably increased frequency of 20q gain (70%) and high levels of copy-neutral
loss of heterozygosity (40%) were observed. The most frequent tumor-speciﬁc CNVs included ampliﬁcations
(7p21.3-15.1, 8q13.3-24.3, 13q14.1-33.3 and 20q12-13.33) and deletions (8p11.23-23.1, 15q11.2-26.1,
17p13.1-13.3 and 18q11.2-21.33). In addition, 10 novel CNVs were discovered and led to identiﬁcation of
WDR16 and RAPGEF5 as candidate genes involved in tumorigenesis, displaying a robust correlation between
expression and genomic alterations. Moreover, WDR16 and RAPGEF5 exhibited altered protein expression
levels as assessed by immunohistochemistry (IHC) in 41 other independent samples. Finally, high consisten-
cies (68–84%) were observed between CNVs by Array and quantitative PCR. These ﬁndings are important for
further elucidating MSS HNPCC pathogenesis.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Hereditary non-polyposis colorectal cancer (HNPCC) syndrome
was initially deﬁned according to data based on family history. Over
the last several years, germline mutations in mismatch repair
(MMR) genes (MSH2, MLH1, MSH6, PMS1, and PMS2) have been
identiﬁed as the causative factors for this syndrome. Families with
cancers that segregate with germline MMR gene mutations are de-
ﬁned as having Lynch syndrome. However, approximately half of
the families that fulﬁll the more stringent revised Amsterdam criteria
for HNPCC do not have evidence of MMR deﬁciency, and therefore,
their tumors are considered microsatellite stable (MSS) [1]. Clinically
deﬁned HNPCC patients with the MSS phenotype (MSS HNPCC) have
clinicopathological characteristics and molecular features that are
distinct from those of HNPCC patients with the microsatelliterectal cancers; MMR, mismatch
nstability; CNV, copy number
eutral loss of heterozygosity;
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rights reserved.instability (MSI) phenotype (MSI HNPCC) and from those of patients
with sporadic colorectal cancers; these factors suggest that other un-
known genes could be involved [2,3]. Because of the gap between the
clinical classiﬁcation and current molecular diagnostic strategies for
familial colorectal cancers and the limited treatment options available
to these patients, there is an urgent need to further investigate the
molecular events involved in MSS HNPCC.
Comprehensive knowledge of the genomic alteration events
responsible for cancer is a critical foundation for its diagnosis and
prognosis and for developing targeted therapeutics. Recently, copy
number variation (CNV) has been recognized as one of the most im-
portant genomic alterations that plays a role in cancer pathogenesis
[4]. In addition, somatic CNVs can be used to identify regions of the ge-
nome that are involved in disease phenotypes [5,6]. Array comparative
genome hybridization (aCGH) is widely used to identify copy number
variations in genomes [7,8]. However, this technique is limited to iden-
tifying homozygous deletions and cannot distinguish between paternal
and maternal recombination events [9,10]. SNP genotyping array
technology allows for the combined analysis of both copy number
and loss of heterozygosity (LOH) (including classical LOH and
copy-neutral loss of heterozygosity (cnLOH)) throughout the genome,
overcoming the limitations of aCGH [11,12]. However, the commercial
SNP genotyping arrays focus on variants that are present in 5% or more
of the population and feature a limited number of CNV probes. There-
fore, submicroscopic structural variants are poorly captured by
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[13]. The recent introduction of the Affymetrix® CytoScan™ HD Array
(CNV-targeted array), which is based on the validated Genome-Wide
Human SNP Array 6.0 and contains more than 2.6 million markers for
copy number variants and approximately 750,000 SNPs, has enabled
the detection of copy number aberrations with high resolution across
the genome. In addition, the CytoScan™ HD Array provides allelic im-
balance information from SNPs. This array has great power to detect
known and novel chromosome aberrations across the entire human
genome and features unbiasedwhole-genome coverage, with excellent
performance across the entire genome.
In the current study, we performed Genome-Wide CNV analysis on
MSS HNPCC and paired normal colorectal samples with the
Affymetrix® CytoScan™ Human CytoScan HD Array to identify abnor-
mal regions of the genome that might be involved in MSS HNPCC path-
ogenesis. The ultimate goal of this study was to improve the
understanding of the molecular mechanisms of MSS HNPCC and to de-
velop more effective molecular markers for the diagnosis, treatment
and prevention of this type of cancer. To our knowledge, this is the
ﬁrst comprehensive study of the genetic alterations found in MSS
HNPCC to be performed using a powerful CNV-targeted array platform.
2. Materials and methods
2.1. Patient selection and DNA extraction
A total of 126 colorectal cancer patients with a family history sug-
gestive of HNPCC syndrome and who underwent surgery between
2008 and 2011 at the Shanghai Cancer Center (Shanghai, China)
were enrolled in this study. All of these patients were from unrelated
families and fulﬁlled stringent clinical criteria: Amsterdam I/II or
Amsterdam borderline (families fulﬁlling all Amsterdam I/II criteria
with the exceptions that the maximum allowed age of diagnosis
was extended to 60 years old and that gastric cancer could be pres-
ent). Fresh frozen colorectal carcinomas and corresponding normal
tissues (12 blood lymphocyte samples and 8 normal mucosa samples
from more than 5 cm away from primary tumor of the same individ-
ual) were collected from the tissue bank of the Shanghai Cancer
Center (Shanghai, China). The samples used contained more than
90% cancerous or mucosal cells. Genomic DNA was extracted using a
QIAGEN DNA puriﬁcation kit (QIAGEN, Hilden, Germany) according
to the manufacturer's instructions. This study was approved by the
institutional review board of the Fudan University Shanghai Cancer
Center, and patient consent was obtained for the release of all medical
records and tissues.
2.2. Microsatellite analysis and immunohistochemical analysis of MMR
proteins
According to the international guidelines, a panel of microsatellite
markers, including the mononucleotide repeat markers BAT25 and
BAT26 and the dinucleotide repeat markers D5S346, D2S123, and
D17S250, were used to classify MSI. Tumors were deﬁned as MSI-H
if two or more of the markers exhibited instability and as MSI-L if
fewer than two markers were positive for instability. Tumors with
no instability in any of the markers were deﬁned as MSS [14].
To assess the expression status of the MMR proteins (MLH1,
MSH2, MSH6 and PMS2), immunohistochemical staining was
performed on sections of formalin-ﬁxed and parafﬁn-embedded
tumor tissues. The whole tissue slides were stained with antibodies
against MLH1 (clone G168-15, dilution 1:30; BD Pharmingen, San
Diego, CA), MSH2 (clone GB-12, dilution 1:100; Oncogene Research
Products, Boston, MA), MSH6 (clone 44, dilution 1:400; BD Biosci-
ences, San Jose, CA), and PMS2 (clone A16-4, 1:50; BD Biosciences,
San Jose, CA) according to standard protocols and procedures as indi-
cated by the manufacturer. Although few tumor cells exhibitednuclear staining equivalent to that of normal tissue, mismatch repair
proteins were considered to be intact and normally expressed.
2.3. CytoScan HD Array and copy number analysis
The Genome-Wide Human CytoScan HD Array (Affymetrix, CA,
USA) was used to analyze genomic alterations according to the man-
ufacturer's protocol. Brieﬂy, 250 ng of genomic DNA from tumor and
matched normal samples was digested with the restriction enzyme
NspI and then ligated to an adapter, followed by PCR ampliﬁcation
using a single pair of primers that recognized the adapter sequence.
The PCR products were run on a 2% TBE gel to conﬁrm that the major-
ity of products were between 150 and 2000 bp in length. To obtain a
sufﬁcient quantity of PCR product for further analysis, all products
from each sample were combined and puriﬁed using magnetic
beads (Agencourt AMPure, Beckman Coulter, Beverly, MA). The puri-
ﬁed PCR products were fragmented using DNase I and visualized on a
4% TBE agarose gel to conﬁrm that the fragment sizes ranged from 25
to 125 bp. The fragmented PCR products were subsequently
end-labeled with biotin and hybridized to the array. Arrays were
then washed and stained using a GeneChip® Fluidics Station 450
and scanned using an Affymetrix GeneChip® Scanner 3000 7G.
Scanned data ﬁles were generated using Affymetrix GeneChip Com-
mand Console Software, version 1.2, and analyzed with Affymetrix®
Chromosome Analysis Suite v1.2 (ChAS) (Affymetrix Inc., USA).
To calculate copy numbers, the data were normalized to baseline
reference intensities using 270 HapMap samples and another 90
healthy normal individuals. The Hidden Markov Model (HMM) avail-
able within the software package was used to determine the copy
number states and their breakpoints. Thresholds of log2 ratio ≥0.58
and ≤−1 were used to categorize altered regions as CNV gains
(ampliﬁcation) and copy number losses (deletions), respectively.
To prevent the detection of false positive CNVs arising due to in-
herent microarray “noise”, only alterations that involved at least 25
consecutive probes and that were more than 50 kbp in length were
considered in the analysis of gains or losses in our study. Ampliﬁca-
tions and deletions were analyzed separately. To exclude aberrations
representing common normal CNVs, all the identiﬁed CNVs were
compared with those reported in the Database of Genomic Variants
(DGV, http://projects.tcag.ca/variation/).
To identify the genes involved in the CNVs further, we queried the
UCSC database (http://genome.ucsc.edu), Ensemble (http://www.
ensembl.org), and BioGPS (http://biogps.gnf.org). Gene annotation and
gene overlap were determined using the human genome build 19
(hg19) and several widely used online databases (Ensembl: http://
www.ensembl.org; UCSC: http://genome.ucsc.edu; and NetAffx: http://
www.affymetrix.com).
2.4. Candidate CNV analysis
We compared overlapping regions in tumor and in normal samples
to identify tumor-speciﬁc CNVs. Tumor-speciﬁc CNVs were considered
possible candidate variants for MSS HNPCC if they fulﬁlled all of the fol-
lowing criteria: (a) there was overlap between the CNV and any RefSeq
gene or Affymetrix-predicted promoter, in particular those genes/
promoters associated with carcinogenesis or involved in pathways
suspected to be affected in colorectal cancer; and (b) there was a statis-
tically signiﬁcant difference between the frequency of the CNV in the
tumor and normal samples (pb0.05). If the candidate variants did
not appear in the DGV database, they were considered rare novel can-
didate CNVs.
2.5. LOH analysis
For LOH analysis, we utilized the algorithm incorporated in the
ChAS software. Because matched normal DNA was available for all
Table 1
Distributions of copy number variations (CNVs) in different categories in MSS HNPCC.
Category of CNVs No. of
CNVs
No. of
samples
Total CNVs from tumors and matched normal
samples
12,879 40
CNVs from tumors 10,462 20
CNVs from matched normal samples 2417 20
Tumor-speciﬁc CNVsa 4191 20
Tumor-speciﬁc CNVs fulﬁlling one of the following criteria
(a) Gene/promoter overlap 3498 20
(b) At least 2 tumors 2543 20
(c) Signiﬁcantly different from normal samples (pb0.05) 793 19
(d) Not in DGV 52 17
Candidate CNVsb 254 19
Suspected novel candidate CNAsc 39 20
Novel candidate CNVsd 10 17
a Tumor-speciﬁc CNVs means tumor CNVs not found in matched normal mucosa.
b Candidate CNVs means tumor-speciﬁc CNVs fulﬁlling all of the criteria (a)+(c)
simultaneously.
c Suspected novel candidate CNAs means (a)+(b)+(d).
d Novel candidate CNVs means candidate CNVs but not in DGV.
Table 2
Characteristics of each of the 20 tumors analyzed.
Sample
ID
Age,
y
No. of
total
CNVs
No. of
loss (%a)
No. of tumor
speciﬁc
CNVs
Microsatellite
status
Clinical criteria
B1 29 123 5 (4.1) 72 MSSb ACc
B2 47 31 5 (16.1) 16 MSS AC
B3 30 844 389 (46.1) 83 MSS AC
B4 34 238 8 (3.4) 30 MSS AC
B5 47 959 466 (48.6) 422 MSS AC
B6 42 34 14 (41.2) 2 MSS AC
B7 44 441 82 (18.6) 160 MSS AC
B8 40 209 24 (11.5) 7 MSS AC
B9 39 947 493 (52.1) 388 MSS AC borderline 1d
B10 20 845 358 (42.4) 470 MSS AC borderline 1
B11 50 403 194 (48.1) 99 MSS AC borderline 1
B12 50 959 460 (48.0) 437 MSS AC borderline 1
B13 50 596 369 (61.9) 282 MSS AC borderline 1
B14 40 969 648 (66.9) 485 MSS AC borderline 1
B15 51 967 307 (31.7) 557 MSS AC borderline 2e
B16 60 519 121 (23.3) 219 MSS AC borderline 2
B17 57 386 178 (46.1) 115 MSS AC borderline 2
B18 56 7 3 (42.9) 1 MSS AC borderline 2
B19 54 225 41 (18.2) 60 MSS AC borderline 2
B20 59 760 308 (40.5) 286 MSS AC borderline 2
a % means the percentage of loss (the number of loss was divided by the total num-
ber of CNVs).
b MSS means microsatellite stable.
c AC: Amsterdam criteria.
d AC borderline 1: families fulﬁlling all Amsterdam I/II criteria with the exception that
only 1 case gastric cancer could be included in the spectrum of HNPCC-associated cancer.
e AC borderline 2: families fulﬁlling all Amsterdam I/II criteria with the exception that
maximum allowed age of diagnosis was extended to 60 years old.
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and cnLOH (i.e., LOH without a change in copy number). Regions of
LOH/cnLOH that were >3 megabases (Mb) were identiﬁed. The fre-
quency and length were assessed separately. The length of chromo-
some affected by LOH was divided by the length of entire
chromosome arm to determine the percentage of LOH.
2.6. Real-time quantitative PCR validation
To validate the initial CytoScan HD Array data, we randomly se-
lected four genes for real-time quantitative PCR (qPCR) analysis on
an ABI PRISM® 7900HT (Applied Biosystems, Forster City, CA) using
SYBR Green-based quantiﬁcation according to the manufacturer's
protocol (TIANGEN, GERMAN). The genes PHLPP1 and WDR16 were
chosen from among the deleted areas, and the genes CDH22 and
RAPGEF5 were chosen from among the ampliﬁed areas. Primers
were designed using Primer 5 and the human genome reference
assembly (UCSC version hg19, based on National Center for Biotech-
nology Information build 37). The melting curves of all PCR products
indicated that the samples contained single PCR products, and blank
controls were negative. Copy number alterations were assessed
using relative quantiﬁcation methods that compensate for differences
in the ampliﬁcation efﬁciencies of the target and reference genes. The
reference tissues used for the copy number calculations were
matched normal tissues (12 blood lymphocyte samples and 8 normal
mucosa samples from more than 5 cm away from primary tumor of
the same individual). The DNA content was normalized to that of
Line-1, a repetitive element for which the copy number per diploid
genome is similar in normal and tumor cells. Changes in copy number
were calculated using the formula 2−ΔΔct [15].
2.7. Immunohistochemical validation of WDR16 and RAPGEF5 protein
expression
The 20 pairs of array samples and 41 other independent MSS
HNPCC samples were sectioned for immunohistochemical staining
to assess the expression status of WDR16 and RAPGEF5 in the
tumor and matched normal tissues. The whole-tissue slides were
stained with antibodies against WDR16 (dilution 1:400, Bioss Biosci-
ences, Shanghai, China) and RAPGEF5 (clone ID: EPR6882, dilution
1:400, Epitomics Inc., California) according to standard protocols.
Gene expression was assessed based on the overall intensity of mem-
branous/cytoplasmic or nuclear staining within the tumor cells and
on the percentage of cells stained. WDR16 localizes to the cell mem-
brane and cytoplasm, whereas RAPGEF5 is expressed in the nucleus.
2.8. Statistical analysis
Statistical analysis was performed using SPSS®, version 16.0. To
identify signiﬁcant tumor-speciﬁc chromosome alterations, the fre-
quencies of the deletion or ampliﬁcation of each CNV region were
compared between the tumor and matched normal tissues using
Fisher's exact test. Chi-square tests were used to test the signiﬁcance
of the genomic alterations detected by the CytoScan HD Array and
qPCR. A 2-sided pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. CNV analysis of 20 MSS HNPCC tumor tissues and corresponding
normal mucosa using the CytoScan HD Array
Sixty-one patients with the MSS phenotype and normal MMR pro-
tein expression were identiﬁed by MSI analysis and immunohisto-
chemistry. We randomly choose 20 paired MSS HNPCC samples, 8 of
which fulﬁlled the Amsterdam I/II criteria and 12 of which were
Amsterdam borderline, for further genetic alteration proﬁling withthe CytoScan HD CNV platform array. All analyzed tumors and normal
samples had chromosomal aberrations. Of the 14,214 genomic
segments in the 40 samples, we restricted the analysis to the 12,879
segments corresponding to the autosomes (7192 of which showed
ampliﬁcations and 5687 of which showed deletions). A summary of
the CNVs in different categories and detailed information are
presented in Tables 1 and 2, respectively. The number of CNVs in in-
dividual tumors ranged from 7 to 969, with a median of 480, and
the CNVs were dispersed across 7–22 chromosomes. Chromosome 7
and chromosome 4 exhibited the most frequent gains and losses;
chromosome 7 represented 12.3% of all gains and chromosome 4
represented 11.9% of all losses across all tumor samples. Compared
with tumors, the normal samples had fewer chromosomal alterations,
and these alterations centered on different chromosomes. The num-
ber of CNVs in individual normal tissues ranged from 3 to 762, with
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Fig. 1. Genome-wide frequency distribution of tumor-speciﬁc DNA copy number variations (CNVs) across all chromosomes in MSS HNPCC. X-axis: chromosomes; Y-axis:
frequency of DNA copy number aberrations (%). Copy number gains (ampliﬁcations—red) and copy number losses (deletions—blue).
30 W. Chen et al. / Genomics 102 (2013) 27–34a median of 383. The most common gains and losses were observed
for chromosome 11, which represented 11.1% of all gains, and chro-
mosome 7, which represented 9.0% of all losses across all normal
samples, respectively.
Overall, >10% of the autosomal DNA sequence was affected by
CNVs in 65% of the MSS HNPCC tumors. The highest percentage of
affected autosomal DNA was 27%. Broad (>50% of the chromosome
arm) ampliﬁcations were noted for chromosomes 7, 8q, 13q, and
20, and broad deletions were observed for chromosomes 8p, 14q,
15q, 17p, 18, and 20p. In contrast, no more than 6.8% of the genome
was affected by CNVs in any of the matched normal tissues, and no
broad CNVs were observed.3.2. Identiﬁcation of tumor-speciﬁc CNVs
To determine the fraction of alterations that were likely to be tumor
speciﬁc (maybe pathogenic), we compared the altered regions in tu-
mors to those in normal samples. A total of 4191 CNVs in the tumor
DNA that did not overlap with the CNVs in normal DNAwere identiﬁed
and categorized as tumor-speciﬁc CNVs (Table 1 and Fig. 1). These
tumor-speciﬁc CNVs were not present in normal tissues and were
therefore categorized as non-polymorphic CNVs. Among the tumor-
speciﬁc CNVs, 3498 encompassed one or more genes (promoters). A
total of 793 of these 3498 CNVs were signiﬁcantly different from nor-
mal samples (pb0.05). As shown in Fig. 1, the most frequent ampliﬁed
regions were observed on chromosomes 7p21.3-15.1, 8q13.3-24.3,
13q14.1-33.3 and 20q12-13.33, and the most frequent deletions were
found on chromosomes 8p11.23-23.1, 15q11.2-26.1, 17p13.1-13.3
and 18q11.2-21.33. Most of these CNVs have been previously described
in colorectal cancer (CRC). The tumor-speciﬁc CNV on 20q13.2 was theTable 3
10 novel statistically signiﬁcant regions and encoded genes in MSS HNPCC.
Chr Cytoband State Start End Size (k
7 p14.1 Gain 39,323,458 39,401,359 77.90
7 p15.3 Gain 22,196,980 22,379,656 228.76
7 q31.2 Gain 116,243,606 116,380,784 137.17
8 q22.1 Gain 94,909,743 94,975,130 65.38
13 q32.3 Gain 99,372,631 99,597,884 134.77
13 q31.3 Gain 92,746,849 92,909,195 162.34
15 q26.1 Loss 91,299,111 91,407,951 108.84
17 p13.1 Loss 9,457,232 9,559,110 101.87
18 q21.33 Loss 60,262,211 60,800,812 538.60
20 p11.23 Gain 19,240,236 19,679,483 439.24most common gain and present in 70% of tumors. The genes located in
these regions encode CDH22, SLC35C2, ELMO2, ZNF334, OCSTAMP,
and SLC13A3. CDH22 (cadherin 22) has been reported to be
overexpressed in colorectal cancer [16].3.3. Identiﬁcation of novel candidate CNVs
Previously, others [17] have shown that rare CNVs might be re-
sponsible for a signiﬁcant proportion of common diseases. For this
reason, we focused on rare CNVs as an underlying cause of MSS
HNPCC. Candidate tumor-speciﬁc CNVs were deﬁned as non-
polymorphic CNVs that fulﬁlled both of the following criteria:
(a) overlapped with a gene/promoter; and (b) were signiﬁcantly
more frequent in tumor samples than in normal samples (pb0.05).
If candidate tumor-speciﬁc CNVs were rare (not in the DGV), they
were deﬁned as novel candidate tumor-speciﬁc CNVs (Table 1).
By merging the overlapping CNVs identiﬁed in each individual, a
total of 254 nonoverlapping CNVs that encompassed one or more
genes and that were signiﬁcantly more frequent in tumor samples
than in normal samples (pb0.05) were identiﬁed as candidate
tumor-speciﬁc CNVs. Ten of these unique candidate tumor-speciﬁc
CNVs (7 gains and 3 losses) were novel, and these CNVs involved a
total of 15 genes. The sizes of the novel candidate CNVs varied from
65 to 539 kb, with an average of 196 kb.
The 10 novel tumor-speciﬁc CNVs included 7 gains (7p14.1,
7p15.3, 7q31.2, 8q22.11, 13q31.3, 13q32.3, and 20p11.23) and 3
losses (17p13.1, 18q21.33, and 15q26.1). Of them, the 5 CNVs on
chromosomes 7p14.1, 7q31.2, 8q22.11, 13q32.3, and 17p13.1 were
detected in more than 45% of samples (Table 3). The top candidate
gene found in region 7p15.3 was RAPGEF5. RAPGEF5 (Rap guanineb) Marker count Overlap genes No. of patients (%)
1 134 POU6F2 12 (60)
9 228 RAPGEF5 7 (35)
8 360 MET 9 (45)
7 98 PDP1 12 (60)
7 248 SLC15A1, DOCK9 11 (55)
6 372 GPC5 8 (40)
176 BLM 8 (40)
8 106 WDR16, STX8, USP43 9 (45)
1 461 PHLPP1, BCL2 8 (40)
7 472 SLC24A3, LOC100130264 8 (40)
31W. Chen et al. / Genomics 102 (2013) 27–34nucleotide exchange factor 5) serves as a RAS activator by promoting
the acquisition of GTP to maintain the active GTP-bound state and is
the key link between cell surface receptors and RAS activation [18].
WDR16 (WD repeat domain 16), located in 17p13.1, plays crucial
roles in a wide range of physiological functions, including signal
transduction, RNA processing, cytoskeleton remodeling, the regula-
tion of vesicular trafﬁc, and cell division [19]. The chromosome region
18q21.33 exhibited frequent deletions (~60% of our tumor samples)
and encodes PHLPP1 (PH domain leucine-rich repeats protein
phosphatase 1), which represents a family of novel Ser/Thr protein
phosphatases. PHLPP1 and PHLPP2 have been identiﬁed as negative
regulators of Akt in different cancer cells [20,21] and might represent
a therapeutic or diagnostic tool for carcinoma. Other regions encoded
many genes involved in genomic instability and growth regulation,
such as BLM and GPC5, but no gene currently known to be associated
with colorectal cancer carcinogenesis has been identiﬁed in these
regions. We choseWDR16 (17p13.1) and RAPGEF5 (7p15.3) as candi-
date genes to test for an association with CRC because antibodies
were available for these proteins. Immunohistochemical staining
was performed on the array samples, the other 41 independent
tumor samples and the corresponding normal mucosa, which served
as reference samples. Absent or signiﬁcantly reducedWDR16 staining
was found in 7 of the 9 tumors with deletions in 17p13.1. RAPGEF5
overexpression was observed in 5 of the 7 tumors with ampliﬁcations
in 7p15.3. The two remaining samples in each set exhibited the same
levels of WDR16 or RAPGEF5 staining observed in their respective
reference tissues. Representative immunohistochemical staining pat-
terns for WDR16 and RAPGEF5 are shown in Fig. 2. In the 41 indepen-
dent samples, WDR16 exhibited completely absent or signiﬁcantly
reduced expression in 19 tumors, whereas RAPGEF5 expression was
elevated in 21 tumor samples relative to the normal samples.
3.4. Validation of CNVs by real-time qPCR
To validate the CytoScan HD Array data, CDH22, RAPGEF5,
WDR16, and PHLPP1 were randomly selected from among the regions
with tumor-speciﬁc CNVs. RAPGEF5, WDR16, and PHLPP1 are located
in novel candidate CNV regions. The chromosomal locations of the
validated genes were 20q13.2, 7p15.3, 17p13.1, and 18q21.33,
respectively. WDR16 and PHLPP1 relative copy number losses (b0.8)
were detected in at least 42% of all samples, and relative copy number
gains (>2) in CDH22 and RAPGEF5 were detected in at least 35% of all
20 tumors. The ﬁndings for the CytoScan HD Array and those for the
qPCR were consistent in at least 68% of cases (Table 4). No signiﬁcant
differences between the genomic alterations detected by the Cyto HD
array and those detected by qPCR were observed (p>0.05).
3.5. LOH
Paired DNA samples from the same patient allowed us to detect
LOH in the tumor samples. A total of 203 LOH regions were identiﬁed
in 16 of the 20 tumors, and 40% (78/203) of these losses were
copy-neutral events. Twenty-four of the chromosomal regions of LOH
were present in more than one tumor. Among them, 7 regions (29%)
exhibited cnLOH with no concomitant copy number alterations. The
most frequently altered regions were 17p12-p11.1 (4/16), which
exhibited a reduced copy number, and 1q21.2-q21.3 (3/16), which
exhibited no copy number change (Table 4). The highest percentages
of LOH and cnLOH were 23% (on 17p12-p11.1) and 34% (on
17q24.2), respectively (Table 5). In addition, broad LOH was observed
on 12q11-q34, 6q11.2-q26, 9p13.1-pter, and 7p11.1-pter, and broad
cnLOH was observed on 8q21.13-q34.3, 7q11.2-q36.3, and
5q13.2-q35.3. Whether these regions contain novel tumor suppressor
genes associated with colorectal cancer carcinogenesis remains to be
determined.4. Discussion
Previous studies primarily focused on searching for susceptibility
genes in the whole genomes of MSS HNPCC tumors [22]. To date,
few whole-genome studies to identify regions that could harbor
CRC risk genes have been conducted. Abdel-Rahman W.M. et al.
reported that 44% of MSS HNPCC tumors harbor between 7 and 18
chromosome arm alterations (mean, 10.6) using conventional CGH
[1]. The two most recent studies using lower resolution commercial
SNP genotype arrays showed that three MSS HNPCC tumors had an
average of 12 chromosomal alterations and that 30 MSS familiar
CRCs had an average of 7.5 aberrations, respectively [23,24]. Howev-
er, no genomic alterations common to MSS HNPCC tumors have
been identiﬁed to date.
The aim of this study was to identify candidate chromosomal
regions that could be associated with MSS HNPCC using the new
CytoScan HD Array, a powerful professional CNV platform that can
probe regions that could not be analyzed with previous techniques.
To increase the likelihood of ﬁnding underlying genomic alterations,
we carefully selected the study subjects using stringent selection
criteria such as family history and age of diagnosis. Our results
show that deletions in chromosomes 8p, 15q, 17p, and 18q and
gains in chromosomes7p, 8q, 13q, and 20q were common alterations
in these tumors. These results are highly consistent with previously
described genomic alterations in CRC [24]. We found that chromo-
some 20q13.2 gains were present in 70% (14/20) of MSS HNPCC
tumors, consistent with the results of a recent study indicating that
the frequency of 20q gain (77%) is greater in MMR-proﬁcient familial
CRCs than in sporadic CRCs (30–50%) [24]. Ampliﬁcation of 20q13.2
also occurs in breast and other cancers and is associated with aggres-
sive tumor behavior [25]. Differences have also been reported in
20q13.2 copy number between colorectal cancers with and without
liver metastasis [26]. In addition, we identiﬁed 10 novel candidate
CNV regions in MSS HNPCC that were present only in tumor samples
and were not described in the DGV. The number of affected chromo-
some arms ranged from 5 to 39, with an average of 28.5 aberrations.
At the level of the chromosome arm, the MSS HNPCC cancers had sig-
niﬁcantly more gains and losses than previously reported [1,23,24].
All of our results conﬁrm that not only all of the known common
copy number changes but also novel chromosome aberrations and
additional CNVs are detectable by the CytoScan HD Array.
Our study identiﬁed novel candidate CNVs on 7p14.1, 7p15.3,
7q31.2, 8q22.11, 13q31.3, 13q32.3, 15q26.1, 17p13.1, 18q21.33, and
20p11.23. None of these CNVs has previously been reported in
relation to CRC carcinogenesis. Nevertheless, we consider these
CNVs to be interesting candidates because several of the genes in
these regions can be functionally linked to cancer pathogenesis. To
determine the relevance of the candidate genes WDR16 (17p13.1)
and RAPGEF5 (7p15.3) in these regions, we studied the protein ex-
pression of WDR16 and RAPGEF5 in the 20 pairs of array-tested sam-
ples and 41 independent pairs of MSS HNPCC samples. Seven of the 9
tumors with a deletion in 17p13.1 completely lacked or exhibited a
marked reduction in WDR16 staining, and 5 of the 7 tumors with an
ampliﬁcation in 7p15.3 overexpressed RAPGEF5. Moreover, WDR16
and RAPGEF5 exhibited signiﬁcant differences in staining in 46% and
51% of the independent tumor samples, respectively, relative to the
normal samples. Consequently, WDR16 and RAPGEF5 seem to be re-
lated to tumorigenesis. Thus, although further analysis of the mecha-
nisms responsible for reduced or increased protein expression is
required, these genes seem to be interesting candidate tumor sup-
pressor gene (TSG) or oncogene in the 17p13.1 and 7p15.3 regions.
Genes other than RAPGEF5 and WDR16 may also be involved in
CRC. The BLM gene, which is located in 15q26.1, belongs to the
RecQ helicase family and has been implicated in the maintenance of
genomic stability. Germline BLM inactivation causes Bloom syndrome
and is associated with a highly elevated risk of cancer [27]. GPC5
Fig. 2. Signiﬁcant tumor speciﬁc copy number variations (CNVs) and protein expression in MSS HNPCC. Inferred copy number change and protein expression on the upper panel
and lower panel, respectively. (A). Inferred copy number ampliﬁcations of tumor (blue) corresponding to the matched normal samples (green) on chromosome 7 band p15.3
encompassing the putative oncogene RAPGEF5. Dotted line pointing chromosomal loci affected by CNVs. (B) Example of matched normal colon mucosa showing negative RAPGEF5
expression (ampliﬁcation 200×) and (C) RAPGEF5 overexpression in tumor area in a MSS HNPCC case with RAPGEF5 ampliﬁcation on chromosome 7p15.3 (ampliﬁcation 200×).
(D). Inferred copy number alterations showing deletion of WDR16 (chromosome 17 band p13.1) in tumor (pink) but not change in normal mucosa (purple). Dotted line pointing
chromosomal loci affected by CNVs. (E) Matched normal rectal mucosa showing positive WDR16 expression (ampliﬁcation 400×) and (F)WDR16 induced expression in tumor area
in a MSS HNPCC case displaying WDR16 deletion on chromosome 17p13.1 in 400× ampliﬁcation.
32 W. Chen et al. / Genomics 102 (2013) 27–34(Glypican-5), located in 13q31.1, plays a role in the control of cell di-
vision and growth regulation. GPC5 can stimulate rhabdomyosarco-
ma cell proliferation by activating Hedgehog signaling [28]. GPC5
has been associated with the risk of lung cancer [29], and thesubstitution allele of GPC5 rs553717 (AA) correlates signiﬁcantly
with tumor recurrence and shorter disease-free survival [30]. Based
on these results, it has been suggested that GPC5 deﬁciency may be
a potential predictor of adverse outcomes in cancer patients [31].
Table 4
The concordance between the CytoScan HD Array and real-time quantitative PCR
(qPCR). The copy number ampliﬁcations (red) and deletions (blue) were assessed
using qPCR based on values of 2−ΔΔct. Gain=copy number gain in CytoScan HD
Array, Loss=copy number loss in Array, N=copy number unchanged in Array.
NA=QPCR not available. The % consistency between the CytoScan HD Array and
qPCR is indicated at the bottom of the table. For ampliﬁed region the consistency
between CytoScan HD Array vs. qPCR was 80% for CDH22 and RAPGEF5 genes. For de-
leted region the consistencies between CytoScan HD Array vs. qPCR were 84% and 68%
for WDR16, and PHLPP1, respectively.
Sample ID
CDH22 RAPGEF5 WDR16 PHLPP1
Array 2-ΔΔct Array 2-ΔΔct Array 2-ΔΔct Array 2-ΔΔct
B1 Gain 1.247 N 0.830 N 1.061 N 1.063
B2 N 1.404 N 1.035 N 1.120 N 0.903
B3 Gain 1.886 Gain 2.403 N 0.757 Loss 0.748
B4 N 5.217 N 9.470 N NA N NA
B5 Gain 0.893 Gain 3.689 Loss 0.657 N 0.814
B6 N 0.480 N 0.620 N 0.406 N 0.451
B7 Gain 1.594 N 0.685 Loss 0.767 N 0.530
B8 Gain 2.374 N 1.158 N 0.923 N 0.780
B9 Gain 2.845 Gain 1.930 Loss 0.776 N 1.300
B10 Gain 2.191 Gain 1.119 N 0.956 N 0.876
B11 Gain 2.158 Gain 1.097 N 0.814 Loss 1.097
B12 Gain 2.426 N 2.085 Loss 1.189 N 1.335
B13 Gain 1.529 N 1.005 Loss 0.573 Loss 0.292
B14 Gain 1.758 N 1.364 Loss 0.671 Loss 0.638
B15 Gain 1.580 Gain 2.404 Loss 0.637 Loss 1.191
B16 N 1.015 N 1.001 N 0.826 Loss 0.513
B17 Gain 27.253 Gain 2.729 Loss 0.717 Loss 2.346
B18 N 0.843 N 0.933 N 0.916 N 0.508
B19 Gain 1.129 N 1.424 N 0.989 N 0.872
B20 N 0.426 N 0.809 Loss 0.340 Loss 0.335
Consistency 80% 80% 84% 68%
33W. Chen et al. / Genomics 102 (2013) 27–34Another alteration on 7q31.2 encompasses the proto-oncogene MET,
a growth factor receptor that is required for embryonic development
and has been implicated in tumorigenesis, particularly in the devel-
opment of invasive and metastatic disease [32–35]. However, the de-
tailed biological functions of the genes in the regions that are alteredTable 5
Frequency of LOH regions and percentage of LOH in more than one tumor among 16
tumors affected by LOH. The length of chromosome affected by LOH was divided by
the length of entire chromosome arm to determine the percentage of LOH.
LOH
status
Chr Cytoband
start
Cytoband
end
Size
(Mb)
No. of
samples
Frequency
of LOH (%)
Percentage
of LOH (%)
LOH 1 p31.1 p31.1 6.397 3 19 5
1 p32.3 p32.2 3.280 2 13 3
1 p35.2 p34.2 9.195 2 13 7
3 p12.1 p11.1 5.003 2 13 5
3 p21.1 p14.1 12.986 2 13 14
3 p24.1 p23 4.883 2 13 5
3 p25.1 p24.3 5.747 2 13 6
3 q24 q26.1 13.986 3 19 13
7 q36.2 q36.3 6.449 2 13 6
11 q14.2 q14.3 4.491 2 13 5
12 q21.31 q21.33 4.610 2 13 5
17 p12 p11.1 5.352 4 25 23
18 q12.1 q12.2 3.132 3 19 5
18 q11.1 q12.1 10.678 2 13 18
18 q21.1 q21.2 4.028 2 13 7
22 q13.1 q13.1 4.145 2 13 11
22 q13.31 q13.31 7.000 2 13 18
cnLOH 1 q21.2 q21.3 3.416 3 19 3
1 q31.2 q31.3 5.566 2 13 4
5 q31.2 q31.3 4.494 2 13 3
6 p12.1 p11.1 3.100 2 13 5
8 q11.23 q11.23 6.018 2 13 6
17 q24.2 q24.2 1.969 2 13 34
17 q25.3 q25.3 1.410 2 13 24in colorectal carcinogenesis remain to be elucidated in further
studies.
Quantitative PCR was performed to conﬁrm our array data. The
genes CDH22, RAPGEF5, WDR16, and PHLPP1 were randomly selected
from regions with tumor-speciﬁc CNVs for qPCR validation experi-
ments. The consistency measures between the array results and the
qPCR results were 80%, 80%, 84%, and 68% for the CDH22, RAPGEF5,
WDR16, and PHLPP1 genes, respectively. These results revealed that
CytoScan HD Array analysis is an effective method for identifying
DNA copy number alterations.
LOH and cnLOH provide valuable information for identifying TSGs.
We identiﬁed a total of 203 LOH events, 40% (78/203) of which were
copy-neutral. The genome-wide level of cnLOH was in agreement
with a recent report that cnLOHs account for 32% of the aberrations
in MSS familial CRCs [24] and are present at a higher frequency in
these cancers than in sporadic CRC, in which only 14% of aberrations
are cnLOH [36]. The regions affected by LOH and cnLOH contain many
candidate tumor suppressors, including ERK5, MAP2K3, SPECC1, and
FLCN, which may be involved in colorectal tumorigenesis and inva-
sion [37–39]. Further studies based on greater numbers of MSS
HNPCC tumors will be essential for identifying relevant candidate ge-
nomic regions and determining the biological functions of the genes
in these regions.
In conclusion, we used a high-density professional whole-genome
CNV array (Affymetrix CytoScan HD Array) that covers more than 2.6
million markers for copy number and approximately 750,000 SNPs to
deﬁne a comprehensive allelotype for a homogenous group of MSS
HNPCC based on LOH and copy number changes. We observed that
the tumor samples contained more CNVs (median, 519) than the
normal tissues (median, 383) and had high levels of cnLOH (40%).
Moreover, we identiﬁed 10 novel tumor-speciﬁc copy number ampli-
ﬁcations (7p14.1, 7p15.3, 7q31.2, 8q22.11, 3q31.3, 13q32.4, and
20p11.23) and deletions (17p13.1, 18q21.33, and 15q26.1) that may
be involved in MSS HNPCC pathogenesis. Two interesting candidate
genes from these regions exhibited signiﬁcant expression alterations
in the array samples and in the independent tumor samples relative
to the normal samples. High correlations (68–84%) were observed
between the CNVs identiﬁed by CytoScan HD Array analysis and sub-
sequently tested by qPCR. Genomic regions with frequent copy gain
or loss in tumors have been suggested to harbor relevant TSGs and
oncogenes. Our study provides new insights into the genetic alter-
ations associated with MSS HNPCC; however, a larger number of sam-
ples are needed to conﬁrm the relevance of these gains and losses to
MSS HNPCC pathogenesis. Further functional and biological investiga-
tions are needed to determine the roles of the newly identiﬁed
potential TSGs and oncogenes in these regions.
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